Phase 1 Dose Escalation Study of LY2334737 Using 2 Dosing Regimens in Patients With Advanced and/or Metastatic Solid Tumors

Trial Profile

Phase 1 Dose Escalation Study of LY2334737 Using 2 Dosing Regimens in Patients With Advanced and/or Metastatic Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs LY 2334737 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 16 Sep 2015 Results published in the Investigational New Drugs.
    • 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Sep 2012 Planned End Date changed from 1 Aug 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top